Q-linea AB (publ) (3F8.F)
- Previous Close
0.0001 - Open
0.0010 - Bid 0.0021 x --
- Ask 0.0062 x --
- Day's Range
0.0010 - 0.0010 - 52 Week Range
0.0001 - 0.3610 - Volume
1,250,000 - Avg. Volume
32,828 - Market Cap (intraday)
2.9B - Beta (5Y Monthly) 0.95
- PE Ratio (TTM)
0.01 - EPS (TTM)
0.2000 - Earnings Date Jul 10, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Q-linea AB (publ) engages in the development of instruments and consumables for infection disease diagnostics in the United Kingdom. The company offers ASTar, an antimicrobial susceptibility testing technologies used in the treatment of bloodstream infections and sepsis. It also develops Podler, a portable blood culture unit for incubating and detecting growth in blood bottles. It serves to physicians, hospitals, laboratories, healthcare payers and the medical profession. The company was incorporated in 2007 and is headquartered in Uppsala, Sweden.
qlinea.comRecent News: 3F8.F
View MorePerformance Overview: 3F8.F
Trailing total returns as of 5/30/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 3F8.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 3F8.F
View MoreValuation Measures
Market Cap
289.98M
Enterprise Value
273.04M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.03
Price/Book (mrq)
0.01
Enterprise Value/Revenue
59.79
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-67.66%
Return on Equity (ttm)
-162.41%
Revenue (ttm)
8.94M
Net Income Avi to Common (ttm)
-206.13M
Diluted EPS (ttm)
0.2000
Balance Sheet and Cash Flow
Total Cash (mrq)
68.03M
Total Debt/Equity (mrq)
42.11%
Levered Free Cash Flow (ttm)
-107.39M